AR041835A1 - Compuestos de purina y usos de los mismos - Google Patents
Compuestos de purina y usos de los mismosInfo
- Publication number
- AR041835A1 AR041835A1 ARP030103918A ARP030103918A AR041835A1 AR 041835 A1 AR041835 A1 AR 041835A1 AR P030103918 A ARP030103918 A AR P030103918A AR P030103918 A ARP030103918 A AR P030103918A AR 041835 A1 AR041835 A1 AR 041835A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- members
- fully saturated
- partially
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- -1 cyano, hydroxy, amino Chemical group 0.000 abstract 31
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 18
- 239000001257 hydrogen Substances 0.000 abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000000623 heterocyclic group Chemical group 0.000 abstract 10
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- 125000002252 acyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 239000000126 substance Substances 0.000 abstract 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 5
- 125000004423 acyloxy group Chemical group 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 5
- 125000002837 carbocyclic group Chemical group 0.000 abstract 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 5
- 150000002431 hydrogen Chemical class 0.000 abstract 5
- 150000003951 lactams Chemical group 0.000 abstract 5
- 150000002596 lactones Chemical group 0.000 abstract 5
- 239000011593 sulfur Chemical group 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 239000005977 Ethylene Substances 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000004442 acylamino group Chemical group 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 239000001301 oxygen Substances 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 2
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 2
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42187402P | 2002-10-28 | 2002-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041835A1 true AR041835A1 (es) | 2005-06-01 |
Family
ID=32176739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103918A AR041835A1 (es) | 2002-10-28 | 2003-10-27 | Compuestos de purina y usos de los mismos |
Country Status (44)
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ527917A (en) * | 1999-11-12 | 2005-03-24 | Biogen Inc | Polycycoalkylpurines as adenosine receptor antagonists |
| US20070129334A1 (en) * | 2001-10-30 | 2007-06-07 | Conforma Therapeutics Corporation | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 |
| EP1440072A4 (en) * | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY |
| AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) * | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| RS20050532A (sr) * | 2003-01-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremeฤaja povezanih sa njim, kao ลกto su dijebetes i hiperglikemija |
| US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7176210B2 (en) * | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7094572B2 (en) | 2003-03-14 | 2006-08-22 | Bristol-Myers Squibb | Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74 |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7268133B2 (en) * | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| CA2524397A1 (en) * | 2003-05-07 | 2004-11-18 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| US7232823B2 (en) * | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| KR20060056944A (ko) | 2003-07-14 | 2006-05-25 | ์๋ ๋ ํ๋ง์ํฐ์นผ์ค, ์ธํฌ. | ๋์ฌ ์กฐ์ ์ ๋ก์ ์ตํฉ๋ ์๋ฆด ๋ฐ ํคํ ๋ก์๋ฆด ์ ๋์ฒด ๋ฐ์ด์ ๊ด๋ จ๋ ์ฅ์ ์ ์๋ฐฉ ๋๋ ์น๋ฃ |
| US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
| US20050043327A1 (en) * | 2003-08-21 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
| US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
| CN101044143A (zh) * | 2004-10-22 | 2007-09-26 | ่พ็ไบงๅๅ ฌๅธ | ๅถๅคๅๅคๅๅ็ฉ็ๆนๆณ |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| AR051596A1 (es) * | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| US9168278B2 (en) | 2004-11-16 | 2015-10-27 | Gw Pharma Limited | Use for cannabinoid |
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| CA2605479A1 (en) * | 2005-04-20 | 2006-10-26 | Pfizer Products Inc. | Acylaminobicyclic heteroaromatic compounds and uses thereof |
| WO2006129193A2 (en) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
| AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| EP1960372B1 (en) | 2005-12-15 | 2015-12-09 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and their uses |
| WO2007075572A2 (en) * | 2005-12-22 | 2007-07-05 | Conforma Therapeutics Corporation | Orally active purine-based inhibitors of heat shock protein 90 |
| US20080027087A1 (en) * | 2006-02-21 | 2008-01-31 | Ampla Pharmaceuticals, Inc. | CB1 antagonists and inverse agonists |
| AU2007219236B2 (en) | 2006-02-23 | 2012-06-21 | Pfizer Limited | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
| WO2007125321A2 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| WO2008044111A1 (en) * | 2006-10-13 | 2008-04-17 | Pfizer Products Inc. | Pharmaceutical formulation tablet |
| CN101583593A (zh) | 2006-11-13 | 2009-11-18 | ่พ็ไบงๅๅ ฌๅธ | ไบ่ณๅบใไบๅกๅถๅบๅ่ณๅบ-ๅกๅถๅบ่ก็็ฉๅๅ ถ็จ้ |
| ATE547394T1 (de) | 2006-12-01 | 2012-03-15 | Bristol Myers Squibb Co | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer fรผr die behandlung von atherosklerose und herz-kreislauf- erkrankungen |
| PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| EP2114933B1 (en) | 2007-01-04 | 2011-09-07 | Prosidion Ltd | Piperidine gpcr agonists |
| CL2008000018A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
| EA016507B1 (ru) | 2007-01-04 | 2012-05-30 | ะัะพะทะธะดะธะพะฝ ะะธะผะธัะตะด | ะะธะฟะตัะธะดะธะฝะพะฒัะต ะฐะณะพะฝะธััั gpcr |
| US20080220104A1 (en) * | 2007-03-08 | 2008-09-11 | Cappello John V | Compositions for producing satiety |
| ES2406129T3 (es) | 2007-10-05 | 2013-06-05 | Verastem, Inc. | Derivados de purina sustituidos con pirimidina |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| CA2705296A1 (en) | 2007-11-21 | 2009-05-28 | Abbott Laboratories | Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators |
| SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| JP5530438B2 (ja) | 2008-08-06 | 2014-06-25 | ใใกใคใถใผใปใชใใใใ | ๏ผญ๏ฝ๏ผไฝๅ่ฌใจใใฆใฎใธใขใผใใณใใใณใธใขใพใซใณๅๅ็ฉ |
| WO2010019762A1 (en) * | 2008-08-13 | 2010-02-18 | Jenrin Discovery | Purine compounds as cannabinoid receptor blockers |
| BRPI0914404A2 (pt) | 2008-10-31 | 2019-03-06 | Genentech Inc | "compostos, composiรงรฃo farmacรชutica e mรฉtodo para tratar ou atenuar a gravidade de uma doenรงa ou condiรงรฃo responsiva ร inibiรงรฃo da atividade jak quinase em um paciente" |
| UA104010C2 (en) | 2008-12-18 | 2013-12-25 | ะญะปะธ ะะธะปะปะธ ะญะฝะด ะะพะผะฟะฐะฝะธ | Purine compounds |
| EP2246335A1 (de) | 2009-02-17 | 2010-11-03 | Bayer CropScience AG | Aminopyrimidinamide als Schรคdlingsbekรคmpfungsmittel |
| DK2414362T3 (da) | 2009-04-03 | 2014-09-22 | Verastem Inc | Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| US8785453B2 (en) | 2009-11-13 | 2014-07-22 | Green Cross Corporation | Arylpiperazine-containing purine derivatives and uses thereof |
| US20130096104A1 (en) * | 2010-03-17 | 2013-04-18 | Genentech, Inc. | Imidazopyridine compounds, compositions and methods of use |
| CN102803263B (zh) * | 2010-03-31 | 2014-12-17 | ไผ่ฑๅฉๅฉๅ ฌๅธ | ็จไฝcb2ๆฟๅจๅ็ๅๅคๅๅ็ฉ |
| AR080711A1 (es) * | 2010-03-31 | 2012-05-02 | Lilly Co Eli | Compuesto de piperazin-purina composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento o prevencion del dolor |
| EP2569310A1 (en) | 2010-05-11 | 2013-03-20 | Pfizer Inc | Morpholine compounds as mineralocorticoid receptor antagonists |
| RU2013114352A (ru) | 2010-09-15 | 2014-10-20 | ะค. ะฅะพััะผะฐะฝะฝ-ะั ะ ะพั ะะณ | ะะทะฐะฑะตะฝะทะพัะธะฐะทะพะปั, ะบะพะผะฟะพะทะธัะธะธ ะธ ัะฟะพัะพะฑั ะฟัะธะผะตะฝะตะฝะธั |
| CN103221410B (zh) | 2010-09-22 | 2017-09-15 | ่พๅฐผ็บณๅถ่ฏๅ ฌๅธ | Gpr119ๅไฝ่ฐ่ๅๅๅฏนไธๅ ถ็ธๅ ณ็้็ข็ๆฒป็ |
| KR20140009259A (ko) | 2010-11-19 | 2014-01-22 | ์ํ. ํธํ๋ง-๋ผ ๋ก์ ์๊ฒ | ํผ๋ผ์กธ๋กํผ๋ฆฌ๋ ๋ฐ tyk2 ์ต์ ์ ๋ก์ ์ด์ ์ฉ๋ |
| BR112014006643A2 (pt) * | 2011-09-20 | 2017-04-04 | Hoffmann La Roche | compostos de imidazopiridina, composiรงรตes e mรฉtodos de uso dos mesmos |
| CZ305750B6 (cs) * | 2012-01-26 | 2016-03-02 | รstav Organickรฉ Chemie A Biochemie Akademie Vฤd ฤr, V.V.I. | Zpลฏsob vรฝroby N-9 substituovanรฝch analogลฏ purinu |
| US9187480B2 (en) | 2012-02-17 | 2015-11-17 | Research Triangle Institute | Peripherally restricted diphenyl purine derivatives |
| RU2485939C1 (ru) * | 2012-06-19 | 2013-06-27 | ะกัะฐะฝะธัะปะฐะฒ ะะฝะฐัะพะปัะตะฒะธั ะะตะดะธะบ | ะััะฐะปัะผะพะปะพะณะธัะตัะบะธะน ะฟัะตะฟะฐัะฐั ะฒ ะฒะธะดะต ะณะปะฐะทะฝัั ะบะฐะฟะตะปั, ัะพะดะตัะถะฐัะธะน ะดะธััะปััะธัะฐะผ ะธ ัะฐััะธะฝ |
| HRP20181141T1 (hr) * | 2013-05-02 | 2018-09-21 | F. Hoffmann - La Roche Ag | Derivati purina kao agonisti cb2 receptora |
| CA2939575A1 (en) | 2014-02-17 | 2015-08-20 | Bayer Cropscience Aktiengesellschaft | 2-(het)aryl-substituted condensed bicyclic heterocycle derivatives as pest control agents |
| HRP20210935T1 (hr) | 2014-05-23 | 2021-08-06 | F. Hoffmann - La Roche Ag | Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak |
| CA3002540C (en) | 2015-01-06 | 2023-11-07 | Arena Pharmaceuticals, Inc. | Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor |
| CN104581617A (zh) * | 2015-01-22 | 2015-04-29 | ๅฐ็ฑณ็งๆๆ้่ดฃไปปๅ ฌๅธ | ๆ ็บฟ้ไฟกๆนๆณๅๆบ่ฝ่ฎพๅค |
| JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | ใขใชใผใ ใใกใผใใทใฅใผใใฃใซใซใบ๏ผ ใคใณใณใผใใฌใคใใใ | ๏ผณ๏ผ๏ผฐ๏ผใฌใปใใฟใผ้ข้ฃ้ๅฎณใซใใใไฝฟ็จใฎใใใฎ๏ผ๏ผฒ๏ผโ๏ผโ๏ผ๏ผโ๏ผ๏ผโใทใฏใญใใณใใซโ๏ผโ๏ผใใชใใซใชใญใกใใซ๏ผใใณใธใซใชใญใท๏ผโ๏ผ๏ผ๏ผ๏ผ๏ผ๏ผ๏ผโใใใฉใใใญใทใฏใญใใณใฟ๏ผป๏ฝ๏ผฝใคใณใใผใซโ๏ผโใคใซ๏ผ้ ข้ ธ๏ผๅๅ็ฉ๏ผ๏ผใฎ็ตๆถๆง๏ผฌโใขใซใฎใใณๅกฉ |
| EP3558996A4 (en) * | 2016-12-21 | 2020-08-05 | Research Triangle Institute, International | DIARYLPURINE DERIVATIVES WITH ENHANCED BIOAVAILABILITY |
| CN110520124A (zh) | 2017-02-16 | 2019-11-29 | ่พๅฐผ็บณๅถ่ฏๅ ฌๅธ | ็จไบๆฒป็ๅๅๆง่ๆฑๆง่็ฎก็็ๅๅ็ฉๅๆนๆณ |
| JP7256757B2 (ja) | 2017-05-22 | 2023-04-12 | ใจใ๏ผ ใใใใณ๏ผใฉ ใญใทใฅ ใขใผใฒใผ | ๅฆ็ฝฎ็จๅๅ็ฉๅใณ็ตๆ็ฉใไธฆใณใซใใฎไฝฟ็จๆนๆณ |
| MX2020010999A (es) | 2018-04-18 | 2021-01-20 | Constellation Pharmaceuticals Inc | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. |
| JP7397011B2 (ja) | 2018-06-06 | 2023-12-12 | ใขใชใผใ ใใกใผใใทใฅใผใใฃใซใซใบ๏ผ ใคใณใณใผใใฌใคใใใ | ๏ผณ๏ผ๏ฝ๏ผๅๅฎนไฝใซ้ข้ฃใใ็ถๆ ใๆฒป็ใใๆนๆณ |
| IL317596A (en) * | 2019-01-15 | 2025-02-01 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Peripheral CB1 receptor inhibitors |
| PE20220562A1 (es) | 2019-07-24 | 2022-04-13 | Constellation Pharmaceuticals Inc | Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3018378A (en) * | 1954-09-20 | 1962-01-23 | North American Aviation Inc | Radiant energy scanning system |
| US3016378A (en) | 1959-07-01 | 1962-01-09 | Thomae Gmbh Dr K | Amino-substituted purine derivatives |
| GB1165283A (en) | 1967-01-17 | 1969-09-24 | Science Union & Cie | New Purine Derivatives and processes for prepararing them |
| AT321295B (de) | 1971-11-11 | 1975-03-25 | Thomae Gmbh Dr K | Verfahren zur Herstellung von neuen Thiazolo[5,4-d]-pyrimidin-Derivaten und ihren Salzen |
| CH653021A5 (fr) | 1981-04-24 | 1985-12-13 | Delalande Sa | Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant. |
| JPS60260579A (ja) | 1984-01-13 | 1985-12-23 | Yoshitomi Pharmaceut Ind Ltd | ใใชใณ่ชๅฐไฝ |
| GB8613591D0 (en) | 1986-06-04 | 1986-07-09 | Roussel Lab Ltd | Chemical compounds |
| US5078780A (en) | 1986-10-22 | 1992-01-07 | Ciba-Geigy Corporation | 1,5-diphenylpyrazole-3-carboxylic acid derivatives for the protection of cultivated plants |
| AU611437B2 (en) | 1987-05-29 | 1991-06-13 | Ortho Pharmaceutical Corporation | Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same |
| US5057517A (en) | 1987-07-20 | 1991-10-15 | Merck & Co., Inc. | Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents |
| PH27357A (en) | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| FR2665898B1 (fr) | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| US5256398A (en) | 1990-11-08 | 1993-10-26 | Whitby Research, Inc. | Composition for determining viability of tissue |
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2714057B1 (fr) | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dรฉrivรฉs du 3-pyrazolecarboxamide, procรฉdรฉ pour leur prรฉparation et compositions pharmaceutiques les contenant. |
| US5596106A (en) | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
| FR2741621B1 (fr) | 1995-11-23 | 1998-02-13 | Sanofi Sa | Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant |
| FR2742148B1 (fr) | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| CN1066448C (zh) | 1996-06-06 | 2001-05-30 | ๆ ชๅผไผ็คพๅคงๅกๅถ่ฏๅทฅๅบ | ้ ฐ่บ่ก็็ฉ |
| CA2278307A1 (en) | 1997-01-21 | 1998-07-23 | Siegfried Benjamin Christensen Iv | Novel cannabinoid receptor modulators |
| FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| WO1998039344A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| FR2761266B1 (fr) | 1997-03-28 | 1999-07-02 | Sanofi Sa | Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates |
| US6579868B1 (en) | 1998-01-05 | 2003-06-17 | Eisai Co., Ltd. | Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes |
| JP3990061B2 (ja) * | 1998-01-05 | 2007-10-10 | ใจใผใถใคใปใขใผใซใปใขใณใใปใใฃใผใปใใใธใกใณใๆ ชๅผไผ็คพ | ใใชใณ่ชๅฐไฝใใใณ็ณๅฐฟ็ ใฎไบ้ฒใปๆฒป็ๅคใจใใฆใฎใขใใใทใณ๏ฝ๏ผๅๅฎนไฝๆฎๆๅค |
| IL141769A0 (en) | 1998-09-11 | 2002-03-10 | Aventis Pharma Sa | Azetidine derivatives, preparation and medicines containing them |
| FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
| WO2001002400A1 (en) * | 1999-07-02 | 2001-01-11 | Eisai Co., Ltd. | Fused imidazole compounds and remedies for diabetes mellitus |
| FR2799124B1 (fr) | 1999-10-01 | 2004-08-13 | Sanofi Synthelabo | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| CA2387138A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Cannabimimetic indole derivatives |
| CA2387892A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| FR2800375B1 (fr) | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| FR2800372B1 (fr) | 1999-11-03 | 2001-12-07 | Sanofi Synthelabo | Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant |
| FR2804604B1 (fr) | 2000-02-09 | 2005-05-27 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac |
| JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ใใชในใใซโใใคใคใผใบใในใฏใคใใใซใณใใใผ | ใซใณใใใใคใใฌใปใใฟใผใขใธใฅใฌใผใฟใผใใใใใฎ่ฃฝ้ ๆนๆณใใใใณๅผๅธ็ณปใใใณ้ๅผๅธ็ณป็พๆฃใฎๅฆ็ฝฎใฎใใใฎใซใณใใใใคใใฌใปใใฟใผใขใธใฅใฌใผใฟใผใฎไฝฟ็จ |
| US6355631B1 (en) | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
| US6566356B2 (en) | 2000-03-03 | 2003-05-20 | Aventis Pharma S.A. | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation |
| US6479479B2 (en) | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
| PL208098B1 (pl) | 2000-03-23 | 2011-03-31 | Solvay Pharm Bv | Pochodne 4,5-dihydro-1H-pirazolu, kompozycja farmaceutyczna, sposรณb wytwarzania zwiฤ zkรณw oraz ich zastosowanie |
| FR2809621B1 (fr) | 2000-05-12 | 2002-09-06 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques |
| US20020019421A1 (en) | 2000-07-05 | 2002-02-14 | Roni Biberman | Compositions and therapy for substance addiction |
| US20020091114A1 (en) | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
| AU2002226674B2 (en) | 2000-12-28 | 2007-03-22 | Ono Pharmaceutical Co., Ltd. | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient |
| CZ2003698A3 (cs) | 2001-03-22 | 2003-06-18 | Solvay Pharmaceuticals B. V. | 4,5-Dihydro-1H-pyrazolovรฉ derivรกty majรญcรญ CB1-antagonistickou รบฤinnost |
| ITMI20011483A1 (it) | 2001-07-11 | 2003-01-11 | Res & Innovation Soc Coop A R | Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi |
| AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
| FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
| JP2005507875A (ja) | 2001-08-31 | 2005-03-24 | ใฆใใใผใทใใฃ ใชใ ใณใใใซใใ | ใซใณใใใใคใๅๅฎนไฝใซไฝ็จใใๆฐ่ฆใชใใฉใพใผใซ้กไผผไฝ |
| TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
| KR100950430B1 (ko) | 2001-09-21 | 2010-04-02 | ์๋ฒ ์ด ํ๋ง์ํฐ์นผ์ค ๋น. ๋ธ์ด | ํจ๋ ฅ์๋ ๏ฝ๏ฝ1-๊ธธํญ ์์ฉ์ ๊ฐ์ง๋4,5-๋ํ์ด๋๋ก-1๏ฝ-ํผ๋ผ์กธ ์ ๋์ฒด |
| CN101659639A (zh) | 2001-09-21 | 2010-03-03 | ็ดขๅฐ็ฆ่ฏ็ฉๆ้ๅ ฌๅธ | ๅ ทๆcb1-ๆฎๆๆดปๆง็ๆฐ็4,5-ไบๆฐข-1h-ๅกๅ่ก็็ฉ |
| US6509367B1 (en) | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
| JP2005532982A (ja) | 2001-09-24 | 2005-11-04 | ใใคใจใซใปใใขใผใใทใฆใผใใซใซใบใปใณใผใใฌใผใทใจใณ | ่ฅๆบใฎๅฆ็ฝฎใฎใใใฎใใญใผใซ่ชๅฐไฝใฎ่ฃฝ้ ๅใณไฝฟ็จ |
| EP1432708B1 (en) | 2001-09-24 | 2005-11-30 | Bayer Pharmaceuticals Corporation | Preparation and use of 1,5,6,7-tetrahydropyrrolo 3,2-c]pyridine derivatives for treatment of obesity |
| PE20030547A1 (es) | 2001-09-24 | 2003-08-18 | Bayer Corp | Derivados de imidazol para el tratamiento de la obesidad |
| SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| US20030139386A1 (en) | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
| AU2003219934A1 (en) | 2002-03-06 | 2003-09-22 | Merck And Co., Inc. | Method of treatment or prevention of obesity |
| ATE486842T1 (de) | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Substituierte amide |
| AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
| AU2003215024B2 (en) | 2002-03-26 | 2008-02-21 | Merck Sharp & Dohme Corp. | Spirocyclic amides as cannabinoid receptor modulators |
| ES2192494B1 (es) | 2002-03-27 | 2005-02-16 | Consejo Superior De Investigaciones Cientificas | Derivados de 1,2,4-triazol con propiedades cannabinoides. |
| FR2837706A1 (fr) | 2002-03-28 | 2003-10-03 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles |
| EP1492784A4 (en) | 2002-03-28 | 2006-03-29 | Merck & Co Inc | SUBSTITUTED 2,3-DIPHENYLPYRIDINES |
| AU2003226149A1 (en) | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Substituted aryl amides |
| FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
| EP1499306A4 (en) | 2002-04-12 | 2007-03-28 | Merck & Co Inc | BICYCLIC AMIDE |
| US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| WO2003095455A2 (en) | 2002-05-10 | 2003-11-20 | Smithkline Beecham Corporation | Substituted pyrazolopyrimidines |
| BR0314872A (pt) | 2002-10-18 | 2005-08-02 | Pfizer Prod Inc | Ligandos do receptor canabinรณide e usos dos mesmos |
| US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US20050043327A1 (en) * | 2003-08-21 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| CN101044143A (zh) * | 2004-10-22 | 2007-09-26 | ่พ็ไบงๅๅ ฌๅธ | ๅถๅคๅๅคๅๅ็ฉ็ๆนๆณ |
-
2003
- 2003-10-20 US US10/689,381 patent/US7129239B2/en not_active Expired - Fee Related
- 2003-10-21 OA OA1200500128A patent/OA13080A/en unknown
- 2003-10-21 CN CNB2006101625797A patent/CN100478343C/zh not_active Expired - Fee Related
- 2003-10-21 DK DK03751149T patent/DK1558615T3/da active
- 2003-10-21 AT AT03751149T patent/ATE371658T1/de active
- 2003-10-21 JP JP2004546275A patent/JP3954618B2/ja not_active Expired - Fee Related
- 2003-10-21 BR BR0314918-8A patent/BR0314918A/pt not_active IP Right Cessation
- 2003-10-21 SG SG200703819-3A patent/SG148071A1/en unknown
- 2003-10-21 CN CNA2006101625782A patent/CN1955181A/zh active Pending
- 2003-10-21 AU AU2003269368A patent/AU2003269368B2/en not_active Ceased
- 2003-10-21 ES ES03751149T patent/ES2291669T3/es not_active Expired - Lifetime
- 2003-10-21 CN CNB2003801022192A patent/CN100439369C/zh not_active Expired - Fee Related
- 2003-10-21 EP EP03751149A patent/EP1558615B8/en not_active Expired - Lifetime
- 2003-10-21 PT PT03751149T patent/PT1558615E/pt unknown
- 2003-10-21 EA EA200500520A patent/EA008176B1/ru not_active IP Right Cessation
- 2003-10-21 WO PCT/IB2003/004619 patent/WO2004037823A1/en not_active Ceased
- 2003-10-21 RS YUP-2005/0306A patent/RS20050306A/sr unknown
- 2003-10-21 CA CA002503900A patent/CA2503900C/en not_active Expired - Fee Related
- 2003-10-21 DE DE60316012T patent/DE60316012T2/de not_active Expired - Lifetime
- 2003-10-21 KR KR1020057007317A patent/KR100674560B1/ko not_active Expired - Fee Related
- 2003-10-21 UA UAA200504047A patent/UA79507C2/uk unknown
- 2003-10-21 MX MXPA05003882A patent/MXPA05003882A/es active IP Right Grant
- 2003-10-21 NZ NZ539589A patent/NZ539589A/en not_active IP Right Cessation
- 2003-10-21 AP AP2005003290A patent/AP1916A/xx active
- 2003-10-21 PL PL03376311A patent/PL376311A1/xx not_active Application Discontinuation
- 2003-10-21 HR HR20050378A patent/HRP20050378A2/hr not_active Application Discontinuation
- 2003-10-21 GE GEAP20038773A patent/GEP20084325B/en unknown
- 2003-10-22 DO DO2003000742A patent/DOP2003000742A/es unknown
- 2003-10-22 TW TW092129337A patent/TWI327567B/zh not_active IP Right Cessation
- 2003-10-23 MY MYPI20034057A patent/MY140010A/en unknown
- 2003-10-24 PE PE2003001082A patent/PE20040781A1/es not_active Application Discontinuation
- 2003-10-27 EG EG2003101003A patent/EG24662A/xx active
- 2003-10-27 AR ARP030103918A patent/AR041835A1/es active IP Right Grant
- 2003-10-27 GT GT200300232A patent/GT200300232A/es unknown
- 2003-10-27 UY UY28044A patent/UY28044A1/es not_active Application Discontinuation
- 2003-10-28 NL NL1024643A patent/NL1024643C2/nl not_active IP Right Cessation
- 2003-11-14 RS YUP-2005/0395A patent/RS20050395A/sr unknown
-
2005
- 2005-04-14 IS IS7801A patent/IS2602B/is unknown
- 2005-04-15 CU CU20050077A patent/CU23535A3/es not_active IP Right Cessation
- 2005-04-26 ZA ZA200503378A patent/ZA200503378B/en unknown
- 2005-04-27 CO CO05040051A patent/CO5560546A2/es not_active Application Discontinuation
- 2005-04-28 EC EC2005005767A patent/ECSP055767A/es unknown
- 2005-04-28 CR CR7812A patent/CR7812A/es unknown
- 2005-04-28 MA MA28239A patent/MA27479A1/fr unknown
- 2005-04-28 TN TNP2005000121A patent/TNSN05121A1/fr unknown
- 2005-05-25 NO NO20052512A patent/NO332195B1/no not_active IP Right Cessation
-
2006
- 2006-07-10 US US11/456,406 patent/US20060241120A1/en not_active Abandoned
- 2006-12-12 JP JP2006334714A patent/JP2007099779A/ja active Pending
-
2007
- 2007-10-19 CY CY20071101350T patent/CY1107505T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044539A1 (es) | Ligandos de receptores de canabinoides y sus usos | |
| AR043038A1 (es) | Compuestos de pirazolotriazina y usos de los mismos | |
| CO5560546A2 (es) | Compuestos de purina y usos de los mismos | |
| ES2515095T3 (es) | Derivados de adamantil acetamida como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
| ES2515194T3 (es) | Derivados de pirrolidina | |
| ES2594409T3 (es) | Derivados de heteroarilo como moduladores del nAChR รก7 | |
| CO5640117A2 (es) | Derivados de 2,4-diamonopirimidina | |
| AR048669A1 (es) | Derivados biciclicos de bisamida | |
| PE20090820A1 (es) | Derivados de piperidina/piperazina | |
| CO5640111A2 (es) | Ligandos del receptor cannabinoide y usos de los mismos | |
| AR049647A1 (es) | Cis-imidazolinas | |
| AR092490A2 (es) | Indolil alquil amino derivados sustituidos como inhibidores de la histona desacetilasa | |
| AR064459A1 (es) | Derivados de sulfonamida | |
| AR076900A1 (es) | Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc | |
| ES2382715T3 (es) | Derivados de pirazol[3,4-B]piridina como inhibidores de fosfodiesterasa | |
| NO20075768L (no) | Hydroksybenzamidderivater og deres anvendelse som inhibitorer av HSP90 | |
| CO6241121A2 (es) | Derivados de azapeptidps | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| CO5680399A2 (es) | Inhibidores de fosfodiesterasa 4, que incluyen analogos de anilina y difenilamina n-sustituidos | |
| AR047678A1 (es) | Derivados de benzamidas y su uso como activadores de glucoquinasa | |
| AR070193A1 (es) | Terapia combinada que comprende inhibidores de sglt e inhibidores de dpp4, composicion farmaceutica y uso | |
| ECSP056016A (es) | Nuevos derivados de 2-piridinacarboxamida | |
| CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR044795A1 (es) | Derivados de pirido [2,1-a] isoquinolina como inhibidores de la dpp-iv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |